Akero Therapeutics

AKRO

Börsenwert 4,5 Mrd. $

Bagsværd, Denmark and South San Francisco, CA, US, 9 December 2025 – Novo Nordisk and Akero Therapeutics Inc. (“Akero”) (Nasdaq: AKRO) today announced that Novo Nordisk's acquisition of Akero, announced on 9 October 2025, has been completed. With the completion of the transaction, Novo Nordisk has acquired all outstanding shares of common stock and common stock equivalents of Akero for 54 USD per share in cash (or aggregated value of 4.7 billion USD) and a non-transferable Contingent Value Right (“CVR”).

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akero Therapeutics, Inc. (NasdaqGS: AKRO) to Novo Nordisk A/S. Under the terms of the proposed transaction, shareholders of Akero will receive $54.00 per share in cash, and a non-transferable Contingent Value Right entitling its holder to receive a cash payment of $6.00 per share upon full U.S.

PHILADELPHIA , Nov. 12, 2025 /PRNewswire/ --  Berger Montague PC  advises shareholders of Akero Therapeutics, Inc. ("Akero" or the "Company") about an investigation into the Company and members of its Board of Directors for potential breaches of fiduciary duties and violations of the federal securities laws. Shareholders of Akero may learn more about this investigation by contacting Berger Montague: Andrew Abramowitz at [email protected] or (215) 875-3015 or Radha Raghavan at [email protected] or (215) 875-4698, or   CLICK HERE.

Post-hoc analyses corroborate previously reported antifibrotic effects of efruxifermin observed in 96-week Phase 2b SYMMETRY trial and indicate potential to reduce risk of disease progression in compensated cirrhosis (F4c) due to MASH

PHILADELPHIA , Nov. 4, 2025 /PRNewswire/ --  Berger Montague PC  advises shareholders of Akero Therapeutics, Inc. ("Akero" or the "Company") about an investigation into the Company and members of its Board of Directors for potential breaches of fiduciary duties and violations of the federal securities laws. Shareholders of Akero may learn more about this investigation by contacting Berger Montague: Andrew Abramowitz at [email protected] or (215) 875-3015 or Radha Raghavan at [email protected] or (215) 875-4698, or   CLICK HERE.

PHILADELPHIA , Oct. 29, 2025 /PRNewswire/ --  Berger Montague PC advises shareholders of Akero Therapeutics, Inc. ("Akero" or the "Company") about an investigation into the Company and members of its Board of Directors for potential breaches of fiduciary duties and violations of the federal securities laws. Shareholders of Akero may learn more about this investigation by contacting Berger Montague: Andrew Abramowitz at [email protected] or (215) 875-3015 or Radha Raghavan at [email protected] or (215) 875-4698, or   CLICK HERE.

Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and offer dividend yields even higher than IT, as well as oil and gas stocks. In this article, I reveal my top 3 Big Pharma players.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akero Therapeutics, Inc. (NasdaqGS: AKRO) to Novo Nordisk A/S. Under the terms of the proposed transaction, shareholders of Akero will receive $54.00 per share in cash, and a non-transferable Contingent Value Right entitling its holder to receive a cash payment of $6.00 per share upon full U.S. regu.

NEW YORK, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Akero Therapeutics, Inc. (NASDAQ: AKRO ) related to its sale to Novo Nordisk A/S. Under the terms of the proposed transaction, Akero shareholders will receive $54.00 per share in cash, and a non-transferable contingent value right entitling its holder to receive a cash payment of $6.00 per share upon full U.S. regulatory approval of efruxifermin by June 30, 2031. Is it a fair deal?

Akero Therapeutics is being acquired by Novo Nordisk for up to $5.2 billion, driven by strong phase 2b results for EFX in F2/F3 pre-cirrhotic and compensated cirrhosis F4 MASH patients. Akero's EFX showed unprecedented reversal of cirrhosis and significant fibrosis improvement in the HARMONY and SYMMETRY studies, respectively, positioning it as a leader in FGF21 analogs. The acquisition includes $54 per share upfront as cash and a $6 per share CVR contingent on FDA approval for compensated cirrhosis due to MASH patients by 2031.